Nils Glenjen

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction

Fredrik Klevebro, Gabriella Alexandersson von Döbeln, N. Wang et al. · Annals of Oncology · 2016 · 396 citations

Medicine, Oncology, Surgery +16

Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial

Gabriella Alexandersson von Döbeln, Fredrik Klevebro, A-B Jacobsen et al. · Diseases of the Esophagus · 2018 · 163 citations · Full text

Medicine, Oncology, Surgery +17

Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer

Morten Lapin, Satu Oltedal, Kjersti Tjensvoll et al. · Journal of Translational Medicine · 2018 · 140 citations · Full text

Medicine, Molecular Biology, Oncology +13

Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts.

Øystein Bruserud, Anita Ryningen, Line Wergeland et al. · PubMed · 2004 · 85 citations

Medicine, Cell Biology, Oncology +9